… drug discovery and what that implies for future developments. To address this question, we
systematically evaluated over 100 drugs, 200 target … delivering novel therapeutic agents in a …

… Particularly, it has been confirmed that drug repositioning has … drug repositioning. In this
review, we systematically reviewed a series of representative drugs that have been repositioned …

… All these evidences indicate the possibility of repurposing PARP1 inhibitors as a safe
therapeutic agent to treat the current acute lung disease caused by SARS-CoV-2 infection. In …

… All these evidences indicate the possibility of repurposing PARP1 inhibitors as a safe
therapeutic agent to treat the current acute lung disease caused by SARS-CoV-2 infection. In …

… This approach to drug discovery offers … drug targets and drug repurposing opportunities.
As an example of disease module‐based insight into disease mechanism, consider pulmonary …

… value in discovering novel therapeutic agents. Most notably, … drug targets for old drugs,
undiscovered drug–drug similarities … antidepressants to treat patients with small-cell lung cancer (…

… human lung cells treated with ACE2 inhibitor and human lung … based on the results
descriptions. If not, the conclusion "our drug repositioning pipeline has shown merit in discovering …

… drug discovery. [1] The history of medicine has been marked by several examples of repositioned
drugs, including some very old drugs… produces to treat pulmonary arterial hypertension…

… primarily focused on therapeutic agents that possessed activity … and discovery of therapeutic
agents that identifies new … pulmonary injury and pulmonary hypertension, indicating that …

… Moreover, researchers only need 1–2 years to identify new drug targets and about an … -2
(severe acute respiratory syndrome coronavirus-2). The antiviral effect of an older antimalarial …